

Message

From: Borges, Shannon [Borges.Shannon@epa.gov]
Sent: 2/16/2016 2:18:06 PM
To: Wozniak, Chris [wozniak.chris@epa.gov]; Kough, John [Kough.John@epa.gov]; McNally, Robert [McNally.Robert@epa.gov]; Nesci, Kimberly [Nesci.Kimberly@epa.gov]; Carlisle, Sharon [Carlisle.Sharon@epa.gov]; Mendelsohn, Mike [Mendelsohn.Mike@epa.gov]
CC: Hartman, Mark [Hartman.Mark@epa.gov]
Subject: RE: Wobachia -- EUP

I agree with the below and can't add much more except that the logistics and cost of doing experimental work in PR may be more difficult for a small company compared to testing in the continental U.S.

MosquitoMate just submitted an application to extend their EUP with the ZAP strain of Wolbachia (this is the strain that we met about last month to discuss an upcoming Section 3). The unanswered question at our meeting was whether they were able to show sufficient efficacy given the type of data they collected in their EUP (field data as opposed to lab or microcosm data). Once they get their application squared away (they did not realize it is a PRIA action) we can ask them if they have interest in testing in PR, but we'll also need to make certain that that work will yield acceptable efficacy data. I'll ask Ann to follow up with whoever is handling efficacy in RD.

Shannon

From: Wozniak, Chris
Sent: Friday, February 12, 2016 12:42 PM
To: Kough, John <Kough.John@epa.gov>; McNally, Robert <McNally.Robert@epa.gov>; Nesci, Kimberly <Nesci.Kimberly@epa.gov>; Carlisle, Sharon <Carlisle.Sharon@epa.gov>; Borges, Shannon <Borges.Shannon@epa.gov>; Mendelsohn, Mike <Mendelsohn.Mike@epa.gov>
Cc: Hartman, Mark <Hartman.Mark@epa.gov>
Subject: RE: Wobachia -- EUP

I agree with John's take on this. I can add that Oxitec initially approached FDA about testing their male sterile mosquitoes in PR, but then for reasons unexplained, dropped the idea, at least for now. One of the FDA folks opined that they thought the setup on the ground and any infrastructure they may need (say from a mosquito control district person) were not as likely in PR as compared to FL. Economic situation in PR is bad, but with the Zika, dengue and chikungunya issues, I'll bet Oxitec would jump at the chance to experiment in PR.

Chris

From: Kough, John
Sent: Friday, February 12, 2016 12:10 PM
To: McNally, Robert <McNally.Robert@epa.gov>; Nesci, Kimberly <Nesci.Kimberly@epa.gov>; Carlisle, Sharon <Carlisle.Sharon@epa.gov>; Borges, Shannon <Borges.Shannon@epa.gov>; Wozniak, Chris <wozniak.chris@epa.gov>; Mendelsohn, Mike <Mendelsohn.Mike@epa.gov>
Cc: Hartman, Mark <Hartman.Mark@epa.gov>
Subject: RE: Wobachia -- EUP

Bob,

I don't know if we have suggested locations to U of Kentucky. I am sure they need cooperators so maybe we could let them know to add PR to EUP for next year. Not sure what the needs are for switching production of mosquito adapted to more tropical environment and increased amounts to treat PR.

John Kough

Sent from my Windows Phone

From: McNally, Robert

Sent: 2/12/2016 11:45 AM

To: Nesci, Kimberly; Carlisle, Sharon; Borges, Shannon; Wozniak, Chris; Mendelsohn, Mike; Kough, John

Cc: Hartman, Mark

Subject: Wobachia -- EUP

For the Zeka Virus fire drill, folks want to know about how we can help our Puerto Rican colleagues address mosquito issues.

I realize the EUP is in year # 3 only in the continental US – Kentucky, Cal and NY—and I realize we are not sure what their plans are for a sec. 3.

BUT, do we ever suggest to folks like the ones at the Univ of Kentucky WHERE they do their EUP?

Thanks,

Bob